Natural Product Research
June 2, 2026
Genís Ona, Cristina Llagostera, Oscar Alvarez et al.
Psilocybin, the main psychoactive compound in Psilocybe cubensis mushrooms, has gained considerable attention for its therapeutic potential. Current research focuses only on isolated psilocybin, neglecting the broader pharmacological and cultural use of the whole mushroom. This perspective advocates for an integrative approach that includes standardised P. cubensis extracts within the...
Discover Mental Health
March 19, 2026
Àlvar Farré-colomés, Olga Rublinetska, Oscar Soto-Angona
Psilocybin-assisted therapies are innovative therapeutic approaches, particularly in the treatment of depression. However, there are sparse studies providing functional magnetic resonance imaging (fMRI) evidence elucidating the underlying biological mechanisms that support clinical outcomes. This review aims to comprehensively gather all the evidence reported in psilocybin studies using fMRI...
The Lancet Regional Health - Europe
November 20, 2025
Santiago Madero, Oscar Soto-Angona, Genís Ona et al.
9 citations
In this viewpoint, we explore the evolving landscape of psychedelic-assisted therapy in Europe, focusing on clinical, regulatory, and therapeutic developments. While access remains limited, recent initiatives in Switzerland, Germany, and the Czech Republic illustrate growing momentum toward regulated use. We examine the debate surrounding psychedelics as pharmacological agents versus...
Scientific Reports
September 1, 2025
Oscar Soto-Angona, Óscar Andión, Pablo Sabucedo et al.
3 citations
Preliminary evidence suggests that ayahuasca may alleviate severe grief symptoms. This three-arm, sequentially allocated, open-label study examines the therapeutic changes associated with ayahuasca-assisted meaning reconstruction therapy (A-MR) compared to meaning reconstruction therapy alone (MR) and a no-treatment control (NT). A total of 84 adults experiencing severe grief within 12 months...
Journal of Contextual Behavioral Science
July 1, 2025
Oscar Soto-Angona, Amanda Rodríguez‐Urrutia, Josep Antoni Ramos‐quiroga et al.
1 citation
Altres ajuts: acords transformatius de la UAB
Neuroscience of Consciousness
2025
Christopher Timmermann, James W. Sanders, David Reydellet et al.
19 citations
5-MeO-DMT is a short-acting psychedelic that is anecdotally reported to induce a radical disruption of the self and a paradoxical quality of aroused, waking awareness that is nevertheless devoid of any specific perceptual contents. Here, we conducted an exploratory observational study of the phenomenological and neuronal effects of this compound. We collected micro-phenomenological interviews,...
European Neuropsychopharmacology
August 1, 2024
Oscar Soto-Angona, Adriana Fortea, Lydia Fortea et al.
7 citations
Seizures are a concerning adverse event frequently associated with the use of psychedelics, and hence, studies involving these substances tend to exclude patients with past history of epilepsy. This is especially relevant because epileptic seizures are markedly increased in the population suffering from mental disorders, and psychedelic assisted therapy is being researched as a promising...
Frontiers in Psychiatry
2024
Pablo Sabucedo, Óscar Andión, Robert A Neimeyer et al.
4 citations
Psychotherapy for Prolonged Grief Disorder (PGD), a condition characterized by an intense and persistent grief response, has received increased attention over the past decades. Evidence-based approaches to prevent PGD are currently scarce, and not always effective. This paper introduces a protocol for a clinical trial exploring the effectiveness of a Meaning Reconstruction psychotherapy...
Clinical Psychopharmacology and Neuroscience
September 6, 2023
Julia Vendrell-Serres, Oscar Soto-Angona, Amanda Rodríguez‐Urrutia et al.
8 citations
Objective: : Treatment Resistant Depression (TRD) is commonly defined as the lack of response to two or more anti-depressants with different mechanisms of action. Up to 30% of patients diagnosed with major depressive disorder might be considered to present TRD. The objective of this study was to assess the effectiveness and tolerability of esketamine in patients diagnosed with TRD, who were...